Publications by authors named "Toko Machida"
Background/aim: The therapeutic efficacy of the paclitaxel (PTX) + cetuximab (Cmab) combination regimen was investigated in patients with recurrence or metastasis after superselective intraarterial chemoradiotherapy (SSIACRT) for oral cancer, and the safety was retrospectively examined.
Patients And Methods: All enrolled patients with advanced oral cancer or who had refused surgery over 10 years from December 2012 to December 2022 underwent SSIACRT for 6 to 9 weeks [cisplatin (CDDP): total 160-630 mg/m and radiotherapy: total 50-70 Gy]. Nine cases (tongue cancer, maxillary gingival cancer, and mandibular gingival cancer; three cases each) were subjected to PTX + Cmab therapy.
Article Synopsis
- Immune checkpoint inhibitors can effectively treat recurrent and metastatic head and neck cancers, but they come with risks of immune-related adverse events (irAEs) due to systemic administration.
- A study was conducted where tumor-bearing mice received either a standard dose or a low local dose of PD-L1 antibodies to evaluate their antitumor efficacy and immune response.
- Results showed that the local low-dose treatment was just as effective as the systemic standard-dose treatment in reducing tumors, with increased levels of important immune proteins in the low-dose group, indicating a promising strategy for treating oral squamous cell carcinoma.
Superselective intra-arterial chemoradiotherapy (SSIACRT) is one of the curative treatments for advanced oral cancer. SSIACRT can reportedly treat cervical lymph node metastases in the level I-IIA area by super selectively catheterizing the facial artery (FA) and infusing drugs. However, since advanced oral cancer lesions involve a number of feeding vessels, retrograde treatment requires the placement of catheters from the superficial temporal artery (STA) and occipital artery (OA).
View Article and Find Full Text PDF